Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Gilteritinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 48,749Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Torys LLP

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Torys LLP

    GILTERITINIB FUMARATE
    arrow
    ChemOutsourcing
    Not Confirmed

    Torys LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2030-05-06

    Date Granted : 2017-02-28

    GILTERITINIB FUMARATE

    Brand Name : XOSPATA

    Patent Number : 2760061

    Filing Date : 2010-05-06

    Strength per Unit : 40 mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2030-05-06

    Date Granted : 2017-02-28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Torys LLP

    GILTERITINIB FUMARATE
    arrow
    ChemOutsourcing
    Not Confirmed

    Torys LLP

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Patent Expiration Date : 2036-07-01

    Date Granted : 2023-08-01

    GILTERITINIB FUMARATE

    Brand Name : XOSPATA

    Patent Number : 2989534

    Filing Date : 2016-07-01

    Strength per Unit : 40 mg

    Dosage Form : TABLET

    Human Or VET : Human

    Route of Administration : ORAL

    Patent Expiration Date : 2036-07-01

    Date Granted : 2023-08-01

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF